SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 124 filers reported holding SAGE THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 2.96 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $4,236,000 | -51.1% | 68,000 | -44.3% | 0.19% | -42.8% |
| Q1 2017 | $8,671,000 | -75.7% | 122,000 | -89.0% | 0.33% | -78.0% |
| Q1 2016 | $35,704,000 | +2.3% | 1,113,654 | +86.0% | 1.52% | +7.4% |
| Q4 2015 | $34,913,000 | +27.1% | 598,854 | -7.7% | 1.42% | +33.1% |
| Q3 2015 | $27,468,000 | +23.4% | 649,064 | +112.8% | 1.06% | +43.3% |
| Q2 2015 | $22,265,000 | -25.6% | 305,000 | -48.8% | 0.74% | -23.4% |
| Q1 2015 | $29,909,000 | +211.2% | 595,443 | +126.7% | 0.97% | +180.9% |
| Q4 2014 | $9,612,000 | -32.3% | 262,625 | -41.7% | 0.34% | -33.3% |
| Q3 2014 | $14,196,000 | – | 450,667 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |